Emtricitabine/Tenofovir Alafenamide Fumarate

恩曲他滨/富马酸磷丙替诺福韦

Report date: 2026/02/14 20:00:22

Base Information

Drug NameEmtricitabine/Tenofovir Alafenamide Fumarate
Drug Alias Name恩曲他滨丙酚替诺福韦F/TAFFTC/TAFEmtricitabine - tenofovir alafenamideEmtricitabine / Tenofovir Alafenamide +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV InfectionsLeukoencephalopathy, Progressive Multifocal
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2016/04/04
Country/TerritoryBelgiumCanadaPanama +[19] 
CombinationsYes EmtricitabineTenofovir Alafenamide Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesJapan Tobacco (Hong Kong) LtdGilead Sciences International LtdGilead Sciences Inc +[6] 
Inactive CompaniesJohns Hopkins UniversityUniversity Of Colorado Denver
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsLeukoencephalopathy, Progressive Multifocal

Other Information

ATC CodeJ05AR17
Related LinksKEGG